Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
NCT ID: NCT01575834
Last Updated: 2024-08-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
7180 participants
INTERVENTIONAL
2012-03-15
2016-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
NCT01631214
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
NCT01992159
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
NCT05067335
Romosozumab/Denosumab Study for Premenopausal IOP
NCT04800367
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
NCT02016716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Romosozumab
Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
Romosozumab
Administered by subcutaneous injection once a month (QM)
Denosumab
Administered by subcutaneous injection once every 6 months (Q6M)
Placebo
Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
Placebo
Administered by subcutaneous injection once a month (QM)
Denosumab
Administered by subcutaneous injection once every 6 months (Q6M)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Romosozumab
Administered by subcutaneous injection once a month (QM)
Placebo
Administered by subcutaneous injection once a month (QM)
Denosumab
Administered by subcutaneous injection once every 6 months (Q6M)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of hip fracture
* Any severe or more than 2 moderate vertebral fractures, as assessed by the central imaging based on lateral spine x-rays
* Use of agents affecting bone metabolism
* History of metabolic or bone disease (except osteoporosis)
* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)
* Current hyper- or hypocalcemia
* Current, uncontrolled hyper- or hypothyroidism
* Current, uncontrolled hyper- or hypoparathyroidism
55 Years
90 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tucson, Arizona, United States
Research Site
Laguna Hills, California, United States
Research Site
Los Angeles, California, United States
Research Site
Sacramento, California, United States
Research Site
Santa Maria, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Lakewood, Colorado, United States
Research Site
Leesburg, Florida, United States
Research Site
Palm Harbor, Florida, United States
Research Site
Plantation, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Gainesville, Georgia, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Bethesda, Maryland, United States
Research Site
Boston, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Asheville, North Carolina, United States
Research Site
Fargo, North Dakota, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Mayfield, Ohio, United States
Research Site
Duncansville, Pennsylvania, United States
Research Site
Denton, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Madison, Wisconsin, United States
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Mar del Plata, Buenos Aires, Argentina
Research Site
Córdoba, Córdoba Province, Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Maroubra, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Herston, Queensland, Australia
Research Site
Keswick, South Australia, Australia
Research Site
Footscray, Victoria, Australia
Research Site
Geelong, Victoria, Australia
Research Site
Heidelberg West, Victoria, Australia
Research Site
Nedlands, Western Australia, Australia
Research Site
Brussels, , Belgium
Research Site
Genk, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Lommel, , Belgium
Research Site
Yvoir, , Belgium
Research Site
Curitiba, Paraná, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Oakville, Ontario, Canada
Research Site
Lachine, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Medellín, Antioquia, Colombia
Research Site
Barranquilla, Atlántico, Colombia
Research Site
Bogota, Cundinamarca, Colombia
Research Site
Bogota, Cundinamarca, Colombia
Research Site
Bogota, Cundinamarca, Colombia
Research Site
Bogota, Cundinamarca, Colombia
Research Site
Bogotá, , Colombia
Research Site
Brno, , Czechia
Research Site
České Budějovice, , Czechia
Research Site
Havlíčkův Brod, , Czechia
Research Site
Klatovy, , Czechia
Research Site
Ostrava-Trebovice, , Czechia
Research Site
Pardubice, , Czechia
Research Site
Pilsen, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Praha 11 - Chodov, , Czechia
Research Site
Uherské Hradiště, , Czechia
Research Site
Zlín, , Czechia
Research Site
Aalborg, , Denmark
Research Site
Århus C, , Denmark
Research Site
Ballerup Municipality, , Denmark
Research Site
Glostrup Municipality, , Denmark
Research Site
Hvidovre, , Denmark
Research Site
Odense, , Denmark
Research Site
Vejle, , Denmark
Research Site
Santo Domingo, Nacional, Dominican Republic
Research Site
Santo Domingo, Nacional, Dominican Republic
Research Site
Santo Domingo, , Dominican Republic
Research Site
Pärnu, , Estonia
Research Site
Tallinn, , Estonia
Research Site
Tartu, , Estonia
Research Site
Berlin, , Germany
Research Site
Bochum, , Germany
Research Site
Dresden, , Germany
Research Site
Dresden, , Germany
Research Site
Frankfurt am Main, , Germany
Research Site
Frankfurt am Main, , Germany
Research Site
Görlitz, , Germany
Research Site
Hamburg, , Germany
Research Site
Hanover, , Germany
Research Site
Heinsberg, , Germany
Research Site
Hellersdorf, , Germany
Research Site
Leipzig, , Germany
Research Site
Magdeburg, , Germany
Research Site
Marburg, , Germany
Research Site
Schkeuditz, , Germany
Research Site
Békéscsaba, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Győr, , Hungary
Research Site
Hévíz, , Hungary
Research Site
Szeged, , Hungary
Research Site
Zalaegerszeg, , Hungary
Research Site
Bangalore, Karnataka, India
Research Site
Mumbai, Maharashtra, India
Research Site
Pune, Maharashtra, India
Research Site
Jaipur, Rajasthan, India
Research Site
Chennai, Tamil Nadu, India
Research Site
Vellore, Tamil Nadu, India
Research Site
Anjyo-shi, Aichi-ken, Japan
Research Site
Urayasu-shi, Chiba, Japan
Research Site
Fukui-shi, Fukui, Japan
Research Site
Fukui-shi, Fukui, Japan
Research Site
Fukui-shi, Fukui, Japan
Research Site
Fukui-shi, Fukui, Japan
Research Site
Fukuoka, Fukuoka, Japan
Research Site
Fukutsu-shi, Fukuoka, Japan
Research Site
Kitakyushu-shi, Fukuoka, Japan
Research Site
Kurume-shi, Fukuoka, Japan
Research Site
Kurume-shi, Fukuoka, Japan
Research Site
Hiroshima, Hiroshima, Japan
Research Site
Chitose-shi, Hokkaido, Japan
Research Site
Ishikari-shi, Hokkaido, Japan
Research Site
Sunagawa-shi, Hokkaido, Japan
Research Site
Akashi-shi, Hyōgo, Japan
Research Site
Kako-gun, Hyōgo, Japan
Research Site
Toride-shi, Ibaraki, Japan
Research Site
Morioka, Iwate, Japan
Research Site
Takamatsu, Kagawa-ken, Japan
Research Site
Kirishima-shi, Kagoshima-ken, Japan
Research Site
Minamikyusyu-shi, Kagoshima-ken, Japan
Research Site
Atugi-shi, Kanagawa, Japan
Research Site
Sagamihara-shi, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Kumamoto, Kumamoto, Japan
Research Site
Sendai, Miyagi, Japan
Research Site
Chiisagata-gun, Nagano, Japan
Research Site
Matsumoto-shi, Nagano, Japan
Research Site
Matsumoto-shi, Nagano, Japan
Research Site
Ueda-shi, Nagano, Japan
Research Site
Ueda-shi, Nagano, Japan
Research Site
Bungoono-shi, Oita Prefecture, Japan
Research Site
Osaka, Osaka, Japan
Research Site
Takatsuki-shi, Osaka, Japan
Research Site
Saga, Saga-ken, Japan
Research Site
Fujimi-shi, Saitama, Japan
Research Site
Matsue, Shimane, Japan
Research Site
Fujinomiya-shi, Shizuoka, Japan
Research Site
Kikugawa-shi, Shizuoka, Japan
Research Site
Tokushima, Tokushima, Japan
Research Site
Hachioji-shi, Tokyo, Japan
Research Site
Kiyose-shi, Tokyo, Japan
Research Site
Minato-ku, Tokyo, Japan
Research Site
Ōta-ku, Tokyo, Japan
Research Site
Setagaya-ku, Tokyo, Japan
Research Site
Shinagawa-ku, Tokyo, Japan
Research Site
Shinagawa-ku, Tokyo, Japan
Research Site
Suginami-ku, Tokyo, Japan
Research Site
Suginami-ku, Tokyo, Japan
Research Site
Toshima-ku, Tokyo, Japan
Research Site
Kofu, Yamanashi, Japan
Research Site
Liepāja, , Latvia
Research Site
Riga, , Latvia
Research Site
Riga, , Latvia
Research Site
Kaunas, , Lithuania
Research Site
Kaunas, , Lithuania
Research Site
Klaipėda, , Lithuania
Research Site
Vilnius, , Lithuania
Research Site
Vilnius, , Lithuania
Research Site
Mexico City, Mexico City, Mexico
Research Site
Monterrey, Nuevo León, Mexico
Research Site
Ciudad Obregón, Sonora, Mexico
Research Site
Christchurch, , New Zealand
Research Site
Grafton, Auckland, , New Zealand
Research Site
Dabrowka Dopiewo, , Poland
Research Site
Elblag, , Poland
Research Site
Krakow, , Poland
Research Site
Lodz, , Poland
Research Site
Świdnik, , Poland
Research Site
Warsaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Bucharest, , Romania
Research Site
Bucharest, , Romania
Research Site
Timișoara, , Romania
Research Site
Barcelona, Catalonia, Spain
Research Site
Pozuelo de Alarcón, Madrid, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Bern, , Switzerland
Research Site
Fribourg, , Switzerland
Research Site
Geneva, , Switzerland
Research Site
Lausanne, , Switzerland
Research Site
Zurich, , Switzerland
Research Site
Zurich, , Switzerland
Research Site
Chorley, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Northwood, , United Kingdom
Research Site
Reading, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.
Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J Bone Miner Res. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17.
Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. J Bone Miner Res. 2019 Sep;34(9):1597-1608. doi: 10.1002/jbmr.3735. Epub 2019 Jun 24.
Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J Bone Miner Res. 2018 Aug;33(8):1407-1416. doi: 10.1002/jbmr.3439. Epub 2018 May 11.
Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3.
Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z.
Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab. 2021 Mar;39(2):278-288. doi: 10.1007/s00774-020-01147-5. Epub 2020 Oct 15.
McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Shi Y, Kanis JA. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int. 2021 Aug;32(8):1601-1608. doi: 10.1007/s00198-020-05815-0. Epub 2021 Feb 3.
Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P. Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. J Bone Miner Res. 2022 Jan;37(1):36-40. doi: 10.1002/jbmr.4457. Epub 2021 Nov 19.
Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20.
Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab. 2020 May;38(3):310-315. doi: 10.1007/s00774-019-01057-1. Epub 2019 Nov 9.
Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab. 2022 Jul;40(4):677-687. doi: 10.1007/s00774-022-01332-8. Epub 2022 May 31.
Eriksen EF, Boyce RW, Shi Y, Brown JP, Betah D, Libanati C, Oates M, Chapurlat R, Chavassieux P. Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment. J Bone Miner Res. 2024 Jul 23;39(6):729-736. doi: 10.1093/jbmr/zjae055.
Lane NE, Betah D, Deignan C, Oates M, Wang Z, Timoshanko J, Khan AA, Binkley N. Effect of Romosozumab Treatment in Postmenopausal Women With Osteoporosis and Knee Osteoarthritis: Results From a Substudy of a Phase 3 Clinical Trial. ACR Open Rheumatol. 2024 Jan;6(1):43-51. doi: 10.1002/acr2.11619. Epub 2023 Nov 20.
McClung MR, Betah D, Deignan C, Shi Y, Timoshanko J, Cosman F. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk. Endocr Pract. 2023 Sep;29(9):716-722. doi: 10.1016/j.eprac.2023.06.011. Epub 2023 Jul 4.
Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, McClung MR. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res. 2024 Sep 2;39(9):1268-1277. doi: 10.1093/jbmr/zjae116.
Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J, Wang Z, Libanati C, Cosman F. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporos Int. 2024 Jul;35(7):1195-1204. doi: 10.1007/s00198-024-07049-w. Epub 2024 Apr 4.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-001456-11
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
20070337
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.